美国代理决策者为重型急性脑损伤患者选择生命支持治疗的预测因素:基于美国人群调查数据的分析
该研究分析了1588名美国在线概率抽样人群的横断面调查数据,其中792人随机接受亲属插管、预后为严重残疾但可能恢复部分意识的假设场景,796人随机接受亲属预计持续植物状态的场景。严重残疾场景中选择生命支持治疗者占15.0%,植物状态场景中占11.4%(p=0.07),两组中选择生命支持治疗者均表现出较低的决策确定性。严重残疾场景的独立预测因素包括高中以下学历(aOR 2.87)、对预后准确性的担忧(aOR 7.64)和对医疗费用的担忧(aOR 4.07);植物状态场景的预测因素包括30-44岁年龄组、男性、英语为第二语言、福音派新教和天主教信仰及低收入。
要点
- 严重残疾预后场景中15.0%的代理决策者选择生命支持治疗,植物状态场景中为11.4%(p=0.07),两组选择者均报告较低的决策确定性。
- 严重残疾场景中,对预后准确性的担忧使选择生命支持治疗的比值比为7.64(95%CI 3.61-16.15)。
- 严重残疾场景中,对医疗费用的担忧使选择生命支持治疗的比值比为4.07(95%CI 1.80-9.18)。
- 植物状态场景中,男性(aOR 3.26,95%CI 1.75-6.06)和天主教信仰(aOR 4.01,95%CI 1.72-9.36)是选择生命支持治疗的独立预测因素。
- 植物状态场景中,30-44岁年龄组(aOR 3.33,95%CI 1.02-10.86)和英语为第二语言(aOR 2.94,95%CI 1.09-7.89)预测选择生命支持治疗。
适用人群与场景
- 美国在线概率抽样人群中的代理决策者,其亲属被设定为因重型急性脑损伤插管,预后为严重残疾但可能恢复部分意识或预计持续植物状态。
研究设计与关键结果
- 研究类型为横断面调查分析,总样本1588人;严重残疾场景792人,植物状态场景796人。
- 严重残疾场景中选择生命支持治疗者占15.0%,植物状态场景中占11.4%(p=0.07),两组中选择生命支持治疗者均表达较低的决策确定性。
- 严重残疾场景的独立预测因素:高中以下学历(aOR 2.87,95%CI 1.23-6.76)、对预后准确性的担忧(aOR 7.64,95%CI 3.61-16.15)、对医疗费用的担忧(aOR 4.07,95%CI 1.80-9.18)。
- 植物状态场景的独立预测因素:30-44岁年龄组(aOR 3.33,95%CI 1.02-10.86)、男性(aOR 3.26,95%CI 1.75-6.06)、英语为第二语言(aOR 2.94,95%CI 1.09-7.89)、福音派新教信仰(aOR 3.72,95%CI 1.28-10.84)、天主教信仰(aOR 4.01,95%CI 1.72-9.36)、低收入(< $25 K)。
证据类型、等级与局限
- 证据类型:横断面调查研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,担忧医疗费用的代理决策者尽管决策确定性高,仍可能倾向于为预计严重残疾的患者选择生命支持治疗。
- 作者认为,代理决策者的多种人口学和决策特征可预测其为不同不良预后程度的重型脑损伤患者选择生命支持治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with a severe acute brain injury admitted to the intensive care unit often have a poor neurological prognosis. In these situations, a clinician is responsible for conducting a goals-of-care conversation with the patient's surrogate decision makers. The diversity in thought and background of surrogate decision makers can present challenges during these conversations. For this reason, our study aimed to identify predictive characteristics of US surrogate decision makers' favoring life-sustaining treatment (LST) over comfort measures only for patients with severe acute brain injury.
METHODS: We analyzed data from a cross-sectional survey study that had recruited 1588 subjects from an online probability-based US population sample. Seven hundred and ninety-two subjects had randomly received a hypothetical scenario regarding a relative intubated with severe acute brain injury with a prognosis of severe disability but with the potential to regain some consciousness. Seven hundred and ninety-six subjects had been randomized to a similar scenario in which the relative was projected to remain vegetative. For each scenario, we conducted univariate analyses and binary logistic regressions to determine predictors of LST selection among available respondent characteristics.
RESULTS: 15.0% of subjects selected LST for the severe disability scenario compared to 11.4% for the vegetative state scenario (p = 0.07), with those selecting LST in both groups expressing less decisional certainty. For the severe disability scenario, independent predictors of LST included having less than a high school education (adjusted OR = 2.87, 95% CI = 1.23-6.76), concern regarding prognostic accuracy (7.64, 3.61-16.15), and concern regarding the cost of care (4.07, 1.80-9.18). For the vegetative scenario, predictors included the youngest age group (30-44 years, 3.33, 1.02-10.86), male gender (3.26, 1.75-6.06), English as a second language (2.94, 1.09-7.89), Evangelical Protestant (3.72, 1.28-10.84) and Catholic (4.01, 1.72-9.36) affiliations, and low income (< $25 K).
CONCLUSION: Several demographic and decisional characteristics of US surrogate decision makers predict LST selection for patients with severe brain injury with varying degrees of poor prognosis. Surrogates concerned about the cost of medical care may nevertheless be inclined to select LST, albeit with high levels of decisional uncertainty, for patients projected to have severe disabilities.
参考来源
- Garg A, Soto AL, Knies AK, et al. Predictors of Surrogate Decision Makers Selecting Life-Sustaining Therapy for Severe Acute Brain Injury Patients: An Analysis of US Population Survey Data. Neurocrit Care. 2021. PMID: 33619667. doi:10.1007/s12028-021-01200-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。